PPAR-γ receptor ligands: novel therapy for pituitary adenomas
J. Clin. Invest. Anthony P. Heaney, et al. 111:1381 doi:10.1172/JCI16575 [
Go to this article.]
Figure 3FACS analysis demonstrated a dose-dependent increase in annexin-FITC immunoreactive human nonfunctioning (
a) and murine gonadotroph (
b) pituitary tumor cells following rosiglitazone treatment in vitro. TUNEL analysis showed increased TMR-red–immunoreactive rat GH3 (
c and
d), mouse αT3 gonadotroph (
e), and human pituitary tumor (
f) cells following rosiglitazone and troglitazone (trog) (10
–5 M) treatment in vitro, confirming TZD-mediated induction of apoptosis (*
P = 0.045; **
P = 0.003; ***
P = 0.0002). TMR red, tetramethylrhodamine-5 (and -6) red. Results are derived from six individual nonfunctioning pituitary tumor cultures and experiments were performed in triplicate wells.
